Explore
Trendline
Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market
Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market
Read More
Trendline
Amazon Expands Healthcare Offerings with Medicare Weight-Loss Drug Program
Amazon Expands Healthcare Offerings with Medicare Weight-Loss Drug Program
Read More
USA Today
Bank of America spends $250M yearly on GLP-1s for workers, CEO says
Bank of America's CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, calling the growing cost a worthwhile investment.
Read More
Trendline
Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition
Novo Nordisk CEO Resets Expectations for Wegovy's Growth Amid Market Competition
Read More
TheStreet
Novo Nordisk CEO resets expectations for Wegovy's explosive growth
I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...
Read More
Trendline
Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio
Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio
Read More
Trendline
Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports
Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports
Read More
Trendline
Eli Lilly Increases 2026 Revenue Forecast Following Strong Q2 Performance
Eli Lilly Increases 2026 Revenue Forecast Following Strong Q2 Performance
Read More
Trendline
Eli Lilly's Q2 Earnings Surpass Expectations, Driven by GLP-1 Drugs
Eli Lilly's Q2 Earnings Surpass Expectations, Driven by GLP-1 Drugs
Read More
Trendline
Eli Lilly's Mounjaro and Zepbound Sales Surge, Outpacing Novo Nordisk
Eli Lilly's Mounjaro and Zepbound Sales Surge, Outpacing Novo Nordisk
Read More
Rapid Read
Senator Tim Sheehy Introduces Bill to Combat Foreign Drug Price Manipulation
Senator Tim Sheehy has introduced the 'Use Sovereignty to Reduce Rx Act' (USTRx Act) to address foreign drug price manipulation, particularly targeting Germany's pricing practices. The bill aims to establish a new pharmaceutical trade negotiator within the U.S. Trade Representative's office and requires annual reports on foreign drug pricing abuses. The legislation seeks to ensure that high-income countries do not use price controls that disadvantage American innovation. Representative Jodey Arrington is leading companion legislation in the House. The bill reflects growing concerns about foreign governments benefiting from American pharmaceutical research while imposing price controls.
Read More
Trendline
Novo Nordisk CEO Emphasizes Innovation Amid Drug Development Setbacks
Novo Nordisk CEO Emphasizes Innovation Amid Drug Development Setbacks
Read More
